Do analysts recommend GLMD or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is GLMD or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% Mainz Biomed N/A N/A N/A

Do analysts rate GLMD or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, GLMD or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is GLMD or QNTM more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% Quantum Biopharma N/A -941.54% -224.41%

Do analysts recommend GLMD or MBRX?

Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 875.61%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, GLMD or MBRX?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A

Is GLMD or MBRX more profitable?

Moleculin Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% Moleculin Biotech N/A N/A -70.93%

Do analysts rate GLMD or LIAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GLMD or LIAN?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is GLMD or LIAN more profitable?

LianBio's return on equity of -33.17% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% LianBio N/A -33.17% -30.19%

Do analysts rate XCUR or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XCUR or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Galmed Pharmaceuticals N/A -35.32% -30.94%

Galmed Pharmaceuticals (GLMD) Competitors

$0.51 -0.03 (-4.99%)

As of 12:04 PM Eastern

Compare

GLMD vs. MYNZ, QNTM, MBRX, LIAN, and XCUR

Should you buy Galmed Pharmaceuticals stock or one of its competitors? MarketBeat compares Galmed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galmed Pharmaceuticals include Mainz Biomed (MYNZ), Quantum Biopharma (QNTM), Moleculin Biotech (MBRX), LianBio (LIAN), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

How does Galmed Pharmaceuticals compare to Mainz Biomed?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Galmed Pharmaceuticals has higher earnings, but lower revenue than Mainz Biomed. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Mainz Biomed	$659.94K	17.30	-$21.65M	-$65.60	N/A

Galmed Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Mainz Biomed	N/A	N/A	N/A

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for Mainz Biomed. Galmed Pharmaceuticals' average media sentiment score of 1.32 beat Mainz Biomed's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Mainz Biomed	Neutral

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats Mainz Biomed on 7 of the 12 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Quantum Biopharma?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Galmed Pharmaceuticals' return on equity of -35.32% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Quantum Biopharma	N/A	-941.54%	-224.41%

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Quantum Biopharma had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 4 mentions for Quantum Biopharma and 3 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 1.32 beat Quantum Biopharma's score of 0.47 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Quantum Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quantum Biopharma is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Galmed Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Summary

Galmed Pharmaceuticals beats Quantum Biopharma on 9 of the 10 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Moleculin Biotech?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 875.61%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Galmed Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Moleculin Biotech. Galmed Pharmaceuticals' average media sentiment score of 1.32 beat Moleculin Biotech's score of 1.29 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Moleculin Biotech	Positive

Moleculin Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Moleculin Biotech	N/A	N/A	-70.93%

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats Moleculin Biotech on 7 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to LianBio?

Galmed Pharmaceuticals (NASDAQ:GLMD) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for LianBio. Galmed Pharmaceuticals' average media sentiment score of 1.32 beat LianBio's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
LianBio	Neutral

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

LianBio's return on equity of -33.17% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
LianBio	N/A	-33.17%	-30.19%

Galmed Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Galmed Pharmaceuticals beats LianBio on 7 of the 11 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Exicure?

Exicure (NASDAQ:XCUR) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

42.8% of Exicure shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Exicure and Exicure both had 3 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 1.32 beat Exicure's score of 1.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Positive
Galmed Pharmaceuticals	Positive

Exicure has a beta of 3.61, meaning that its share price is 261% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals' return on equity of -35.32% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

Exicure has higher revenue and earnings than Galmed Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	20.82	-$4.95M	-$1.55	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Summary

Galmed Pharmaceuticals beats Exicure on 6 of the 10 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.80M	$2.99B	$6.74B	$12.51B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-0.41	18.66	26.90	24.39
Price / Sales	N/A	822.95	587.69	117.46
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	0.18	4.22	10.92	6.33
Net Income	-$10.31M	$64.26M	$3.58B	$330.66M
7 Day Performance	-10.37%	-3.42%	-2.25%	-0.84%
1 Month Performance	-16.67%	2.26%	3.08%	-0.26%
1 Year Performance	-75.60%	20.47%	26.23%	19.99%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.5166 of 5 stars	$0.51 -5.0%	N/A	-72.2%	$2.80M	N/A	N/A	20	Positive News Earnings Report Short Interest Decrease Gap Down
MYNZ Mainz Biomed	0.1763 of 5 stars	$1.34 -6.9%	N/A	-29.2%	$12.14M	$659.94K	N/A	30	High Trading Volume
QNTM Quantum Biopharma	0.2216 of 5 stars	$3.17 -4.5%	N/A	-81.1%	$12.11M	N/A	N/A	N/A
MBRX Moleculin Biotech	2.8121 of 5 stars	$2.28 -1.6%	$22.00 +863.6%	-83.9%	$12.06M	N/A	N/A	20	Positive News
LIAN LianBio	N/A	$0.11 flat	N/A	-74.1%	$11.95M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. MYNZ, QNTM, MBRX, LIAN, and XCUR

How does Galmed Pharmaceuticals compare to Mainz Biomed?

Summary

How does Galmed Pharmaceuticals compare to Quantum Biopharma?

Summary

How does Galmed Pharmaceuticals compare to Moleculin Biotech?

Summary

How does Galmed Pharmaceuticals compare to LianBio?

Summary

How does Galmed Pharmaceuticals compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. MYNZ, QNTM, MBRX, LIAN, and XCUR

How does Galmed Pharmaceuticals compare to Mainz Biomed?

Do analysts recommend GLMD or MYNZ?

Which has better valuation & earnings, GLMD or MYNZ?

Which has more volatility & risk, GLMD or MYNZ?

Is GLMD or MYNZ more profitable?

Does the media favor GLMD or MYNZ?

Do institutionals & insiders have more ownership in GLMD or MYNZ?

Summary

How does Galmed Pharmaceuticals compare to Quantum Biopharma?

Is GLMD or QNTM more profitable?

Do institutionals and insiders have more ownership in GLMD or QNTM?

Does the media prefer GLMD or QNTM?

Do analysts rate GLMD or QNTM?

Which has higher earnings & valuation, GLMD or QNTM?

Which has more volatility & risk, GLMD or QNTM?

Summary

How does Galmed Pharmaceuticals compare to Moleculin Biotech?

Do analysts recommend GLMD or MBRX?

Which has more risk and volatility, GLMD or MBRX?

Does the media favor GLMD or MBRX?

Is GLMD or MBRX more profitable?

Which has preferable earnings & valuation, GLMD or MBRX?

Do institutionals & insiders hold more shares of GLMD or MBRX?

Summary

How does Galmed Pharmaceuticals compare to LianBio?

Do analysts rate GLMD or LIAN?

Does the media prefer GLMD or LIAN?

Which has better valuation & earnings, GLMD or LIAN?

Is GLMD or LIAN more profitable?

Which has more volatility and risk, GLMD or LIAN?

Do institutionals & insiders hold more shares of GLMD or LIAN?

Summary

How does Galmed Pharmaceuticals compare to Exicure?

Do institutionals and insiders hold more shares of XCUR or GLMD?

Does the media refer more to XCUR or GLMD?

Which has more risk & volatility, XCUR or GLMD?

Do analysts rate XCUR or GLMD?

Is XCUR or GLMD more profitable?

Which has stronger valuation & earnings, XCUR or GLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools